|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TNF inhibitor golimumab (GLM) is a treatment option in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
|
30415451 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To identify (1) whether tumor necrosis factor inhibitor (TNFi) drug levels/anti-drug antibodies (ADAb) are associated with treatment response and disability in patients with psoriatic arthritis (PsA); and (2) the factors associated with TNFi drug levels.
|
31371650 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the short-term effects of tumor necrosis factor alpha (TNF-α) and interleukin-17A (IL-17A) inhibition on the structural changes in psoriatic arthritis (PsA) using high-resolution peripheral quantitative computed tomography (HR-pQCT) have been reported, no studies have investigated the long-term structural changes in PsA patients receiving routine care.
|
31801610 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome.
|
30858782 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet's disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA.
|
29623390 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
|
30172115 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthritis (PsA) patients naïve to biologics or inadequate responders to tumor necrosis factor (TNF-IR) inhibitors in real life.
|
29411182 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rheumatoid and psoriatic arthritis are chronic inflammatory diseases, with massive increase of cardiovascular events (CVE), and contribution of the cytokines TNF-α and IL-17.
|
29195855 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
373 controls and 137 SpA (82 with Psoriatic Arthritis-PsA and 55 with Ankylosing Spondylitis- AS; 98/137 under TNFα inhibitor therapy) from the Veneto Region (Italy) were studied.
|
29579081 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study.
|
28772007 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p < 0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p < 0.001) than patients who were classified as axPsA.
|
29948352 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA.
|
29855175 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
This retrospective study aimed to evaluate the long-term efficacy and effects on lipid profile and Atherogenic Index of antitumor necrosis factor (TNF)α therapy with adalimumab in patients with moderate-to-severe psoriasis or psoriatic arthritis.
|
29564871 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
These drugs block TNFα from interacting with its receptors and have enabled the development of breakthrough therapies for the treatment of several autoimmune inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.
|
29518978 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Such genes are involved in molecular pathways crucial for PsA pathogenesis, including immune response, glycolipid metabolism, bone remodeling, type 1 interferon, wingless related integration site, and tumor necrosis factor signaling.
|
30061880 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
More than 15 years ago, tumor necrosis factor inhibitors (TNFi) were the first biologic disease modifying anti-rheumatic drugs (bDMARDs) that were approved for the treatment of PsA.
|
29846825 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn's disease, refractory asthma, and multiple sclerosis.
|
29875003 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis.
|
28837372 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.
|
28966209 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adalimumab is a fully human chimeric tumor necrosis factor inhibitor used to treat immune-mediated disorders such as psoriatic arthritis.
|
29538028 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine treatment patterns and therapy modifications in U.S. patients with PsA receiving a tumor necrosis factor inhibitor (TNFi) or an anti-interleukin (IL)-12/23 inhibitor.
|
29557701 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After correction for multiple testing with a false discovery rate of 5%, two SNPs remained significant: TNF (rs361525) was associated with PsO, PsC10, and PsA; and IL12B (rs6887695) was associated with PsO.
|
29389950 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methotrexate and tumor necrosis factor inhibitors are favored in European League Against Rheumatism guidelines, whereas other conventional synthetic disease-modifying antirheumatic drugs and biologics are equally positioned in Group for Research and Assessment of Psoriasis and PsA recommendations.
|
29035933 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis.
|
30206447 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine treatment patterns and therapy modifications in U.S. patients with PsA receiving a tumor necrosis factor inhibitor (TNFi) or an anti-interleukin (IL)-12/23 inhibitor.
|
29952704 |
2018 |